Psychedelics
November 15, 2025
Meghan DellaCrosse, Shoval Gilead, Rafael Lancelotta et al.
Serotonergic psychedelics like psilocybin and LSD have shown potential therapeutic benefits for mental health conditions, including depression, PTSD, and addiction. However, research remains limited due to regulatory barriers and a lack of diversity in study populations. Spanish-speaking individuals, despite their significant global and U.S. presence, are underrepresented in psychedelic...
Journal of Psychedelic Studies
September 4, 2025
Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda et al.
4 citations
Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistance. Psilocybin-assisted therapy (PAT) shows promise in reducing depressive symptoms, but long-term effects are unknown. We aimed to determine the long-term safety and efficacy of PAT for MDD over a five-year follow-up period. Methods Individuals who...
Journal of Psychoactive Drugs
June 18, 2025
Rafaelle Lancelotta, Meghan DellaCrosse, Diana Quinn et al.
7 citations
This study investigated subjective psychedelic experiences in the global LGBTQIA+ population. Using validated measures of acute psychedelic effects, psychological flexibility, gender and sexual identity attitudes, adverse experiences, and mental health, we examined self-reported changes in identity and mental health outcomes following psychedelic use. A total of 346 individuals completed the...
Journal of Psychedelic Studies
June 5, 2024
Meghan DellaCrosse, Albert Garcia‐romeu, Alan K. Davis
4 citations
Despite growing interest in psychedelic-assisted therapy (PAT) research, there remains a lack of consensus about key issues relevant to difficulties in predicting acute drug effects, and the role of therapeutic support in clinical trials. In the absence of a clear theoretical model to conceptualize multifaceted components in PAT research, dialogue across contexts (e.g., popular media, peer...
PLoS One
December 14, 2022
Meghan DellaCrosse, Mollie Pleet, Emma Morton et al.
28 citations
Objectives People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushrooms,” is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have...
Journal of Affective Disorders Reports
September 22, 2021
David E. Gard, Mollie Pleet, Ellen Bradley et al.
33 citations
Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...
medRxiv
April 7, 2021
David E. Gard, Mollie Pleet, Ellen Bradley et al.
preprint
Abstract Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances) in this population, including a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder. Data Sources: A comprehensive search of case studies published through...